Pharmaceuticals News

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis,...

VALNEVA Declaration of shares and voting rights Status as of October 31, 2026__________________________________________________________________________________________ Company name:...

VALNEVA Déclaration d’actions et de droits de vote Statut au 31 octobre 2026__________________________________________________________________________________________ Dénomination sociale :...

Bagsværd, Denmark, 3 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...

T-Cypher Bio Presents Promising Data on Two T Cell Engager Development Candidates for High Copy Number Cancer Targets at the 2026 Society for Immunotherapy

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, a clinical-stage biotech company harnessing the power of the innate and adaptive immune systems, today announced that two...

New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio...

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...

HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Diakonos Oncology Corp. (“Diakonos”), a clinical-stage biotechnology company developing a new generation of immunotherapies for aggressive cancers, today...

Third quarter revenue of $28.5M, +35% year-over-year growth; IFRS gross margin of 76.6%Third quarter usage fee revenue of $13.3M, +60% year-over-year growthFirst nine months revenue of $82.9M, +41%...